Nielsen, Lene Kongsgaard <br/><br/>
Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients.  [electronic resource] 

 -  European journal of haematology  Jan 2019 
 - 70-78 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1600-0609 
<br/><br/><label>Standard No.: </label>10.1111/ejh.13175  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bortezomib--administration & dosage<br/>Clarithromycin--administration & dosage<br/>Clinical Protocols<br/>Cyclophosphamide--administration & dosage<br/>Denmark--epidemiology<br/>Dexamethasone--administration & dosage<br/>Female<br/>Humans<br/>Induction Chemotherapy<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--diagnosis<br/>Neoplasm Staging<br/>Quality of Life<br/>Treatment Outcome